Skip to main content
. Author manuscript; available in PMC: 2021 May 13.
Published in final edited form as: Curr Res Biotechnol. 2019 Nov 15;1:78–86. doi: 10.1016/j.crbiot.2019.11.001

Figure 5. RADD measures DNA levels in ovarian patient tumor samples.

Figure 5.

A. Basal levels of DNA damage were detected in tumor samples collected in a de-bulking surgery before the start of chemotherapy (pre) and at a second de-bulking surgery when the tumor recurred after treatment with carboplatin and paclitaxel (post). A two-tailed t-test is used to determine significance between pre- and post-treatment tumors for a single patient. B. Representative images of a tumor section imaged from patient 1 and patient 4 pre- and post-treatment are shown. C. Fluorescent intensity of DNA damage staining in the pre-treatment tumor is divided into low, moderate, and high staining categories, so the trend in DNA damage staining intensity pre- and post-treatment can be observed across the eight patient samples.